Malignant Pleural Mesothelioma: an Update for Pulmonologists

Sidhu, Calvinjit; Louw, Amber; Brims, Fraser; Creaney, Jenette; Lee, Y. C. Gary

doi:10.1007/s13665-019-0224-9

Cited by 5 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, the present meta-analysis is the first toelaborate on the significance of SUVmax, TLG, and MTV in predicting MPM prognosis.MPM is a refractory disorder with an increasing incidence worldwide [ 5 , 37 – 39 ]. Some recent meta-analyses have verified that FDG uptake can be applied in predicting the prognosis of cancers like soft tissue sarcoma, hepatocellular carcinoma, and head-and-neck cancer (HNC) [ 40 – 45 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis

Wen

Piao

et al. 2022

Cancer Cell Int

View full text Add to dashboard Cite

Purpose Present work systematically reviewed relevant literature based on 18F-FDG PET parameters and conducted a meta-analysis to examine the prognostic value of maximal standard uptake value (SUVmax), total lesional glycolysis (TLG), and metabolic tumour volume (MTV) in the prognosis of malignant pleural mesothelioma (MPM). Methods The relevant literature published in English were searched on PubMed, Cochrane Library, and EMBASE databases. We also evaluated the significance of SUVmax, TLG, and MTV in prognosis prediction using pooled hazard ratios (HRs). Results The current study comprised 12 primary studies with a total of 1307 MPM cases. According to our results, the pooled HR (95% confidence interval [CI]) of increased SUVmax for overall survival (OS) was 1.30 (95% CI 1.13–1.49, P = 0.000), whereas the increased TLG was 1.81(95% CI 1.25–2.61, P = 0.089). The increased MTV was not significantly related to OS (1.14 [95% CI 0.87–1.50, P = 0.18]).However, study design-stratified subgroup analysis suggested that differences in OS of retrospective and prospective subgroups were statistically significant, and no significant heterogeneity among different studies was observed. Conclusion Based on the findings from the present work, PET/CT can significantly affect the prognosis prediction in MPM cases. Also, the increased SUVmax and TLG values predict an increased risk of mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis

Wen

Piao

et al. 2022

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…19 New diagnostic tests have further strengthened the diagnosis of mesothelioma at the cellular level (see our recent review). 20 In particular, loss of BReast CAncer (BRCA)-associated protein 1 (BAP1) protein, a tumor suppressor gene located at 3p21, by immunostaining and homozygous deletion of cyclin-dependent kinase inhibitor 2A (CDKN2A), a cell-cycle suppressor gene, by fluorescence in situ hybridization (FISH) represent major diagnostic advances. Although both features can be found in other cancers, [21][22][23][24][25][26] these features have never been observed or reported in benign pleural diseases including benign asbestos-related pleural effusion.…”

Section: Newer Molecular/cytopathology Techniquesmentioning

confidence: 99%

Management of Malignant Pleural Effusions—What Is New

Thomas

Roy

Maldonado

et al. 2019

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Malignant pleural effusion (MPE) is a common and challenging problem. Patients affected by MPE have a poor prognosis and suffer from breathlessness and impaired quality of life. The management of MPE has barely changed for many decades; however, recent research has driven new paradigms in the diagnosis and treatment of MPE and stimulated novel concepts that are being evaluated in many ongoing studies. This review provides an overview of recent advances in the diagnosis of MPE, including new cytopathology and imaging techniques, and the landmark studies that provide a solid evidence base to support the use of indwelling pleural catheters as first-line treatment in MPE. Lingering management dilemmas, including optimal chest drainage tube and role of surgery in MPE, and key knowledge gaps that are the focus of ongoing research are also highlighted.

show abstract